Table 3.
Conjugation strategy and different applications.
| Construct | CPP | NP | Delivery Cargo | Applications | Ref. |
|---|---|---|---|---|---|
| MPEG-PCL-TAT+siRNA micelles | TAT | Methoxypoly(ethylene glycol) and poly(ε-caprolactone) | siRNA | Brain cancer | [84] |
| TGN-NP | TGN | PEG-PLGA | Coumarin-6 | BBB targeting | [16] |
| MPEG-PCL-TAT micelles | TAT | MPEG-PCL | Anti RafsiRNA/CPT drug | Glioblastoma | [13] |
| ANG/TAT/DTX | Angiopep-2 and TAT | Tandem micelles | DTX | Glioblastoma | [82] |
| AsTNP | TGN | PEG-PCL | DTX | Glioblastoma | [77] |
| ANG-NP-PTX | Angiopep-2 | PEG-PCL | PTX | Glioblastoma | [79] |
| A-SLN | Angiopep-2 | Solid lipid nanoparticle | DTX/DiR/coumarin-6 | Glioblastoma | [83] |
| AnACNPs | ACPP and Angiopep-2 | PEG-PCL | Coumarin-6/DiR | Glioblastoma | [80] |
| AnACNps | ACPP and Angiopep-2 | PEG-PCL NP | DTX | Glioblastoma | [81] |
| CPP-QD@mSiO2 | ACPP | Mesoporous silica-coated QD | DOX | Cancer | [98] |
| TAT-Au-DOX | TAT | PEG and dodecylamine coated Au NP | DOX | Breast metastatic cancer | [88] |
| AuNP/DOX/TAT/PEG/antibody | TAT-C | Au NP | DOX | Breast cancer | [87] |
| AgNP-RWn | [RW]3,4,5,6 | Silver NP (AgNP) | ---- | Breast cancer | [18] |
| PLGA-TAT-ADM | TAT | Poly(lactic-glycolic acid) | Epirubicin | Hepatic cancer | [90] |
| H+C-NPs | R9 | PLGA-PEG | PTX | Hepatic cancer | [91] |
| TNPs | RLW | PEG-PCL | DTX/coumarin-6/DiR | Lung cancer | [93] |
| PEG2000-peptide-PTX and TATp-PEG1000-PE | TAT | PEG1000-PE | PTX | Lung cancer | [94] |
| CPP-LNP-siRNA | Arginine rich and siRNA carrier | Protamine-decorated lipid NP | SiRNA GFP/luciferase | Melanoma cancer | [19] |
| AuNP-SVS-1/TXR | SVS-1 | AuNP | Texas red dye (TXR) | Cancer | [92] |
| QD-CPP | Ku-70; TAT; hCT; HSV1-VP22; | Quantum dot (CdTE@CdSe@CdS@ZnS) | ---- | Multidrug resistant cancer | [95] |
| STD-NMdrug | TAT | Nanomicelles | DOX | Cancer and Imaging agent | [100] |
| QD-TAT | TAT | Quantum dots coated PEG | ---- | Imaging agent | [101] |
| SPIO-R11 | Arginine rich peptide (R11) | Supermagnetic iron oxide (SPIO) | ---- | Imaging agent MRI (Bladder cancer) |
[99] |
| Gd-DTPA-CPP | L-CPP | DTPA | Gadolinium | Imaging agent | [21] |
| SR9-QD | R9 | Quantum dots (CdSe/Z S) core shell | ---- | Imaging agent | [97] |
| ACPP-GD | ACPP | PAMAM dendrimer | Gadolinium | Imaging agent | [10] |
| Poli(NIPAM)-KAFAK | KAFAK | Thermosensitive polymer poly(N-isopropylacrylamine) | KAFAK | Inflammation | [74] |
| Sta-R8+FA- PPLPNs/MTX | R8 | Lipid polymeric hybrid NP | MTX | Rheumatoid arthritis | [107] |
| APTstat3-9R | R9 | Discoid shaped lipid NP | STAT | Inflammation | [105] |
| K16APoE-TargetedNP-DutchAβ40 | K16ApoE | PGLA | Curcumin | Alzheimer model | [112] |
| Insulin-loaded-TAT-NP | TAT | PLGA | Insulin | Alzheimer disease | [110] |
| DPA-hGDNF | Angiopep-2 | Dendigraft poly-l-lysine (DGL-PEG) and PAMAM dendrimer | Gene therapy (hGDNF) | Parkinson disease | [111] |
| MPEG-PCL-TAT+siRNA micelles | TAT | Poly(ethylene glycol) and poly(ε-caprolactone) | siRNA | Brain cancer | [84] |
Cell-penetrating peptides (CPP); Quantum dot (QD); Supermagnectic iron oxide (SPIO); Poly(ethylene glycol) (PEG); poly(ε-caprolactone) (PCL); nanoparticles (NP); Silver (Ag); gold (Au); Solid Lipid Nanoparticle (SLN); Poly(lactic-glycolic acid) (PLGA); polyamidoamine (PAMAM); Methotrexate (MTX); discoid-shaped lipid NP (DLNP); diethylenetriamine pentaacetic acid (DTPA); placlitaxel (PTX); Doxubicin (DOX); Docetaxel (DTX); small-interfering RNA (SiRNA); Green Fluorescence protein (GFP); Thermosensitive polymer poly(N-isopropylacrylamine) (poli(NIPAM); Sendigraft poly-l-Lysine (DGL); Blood–brain barrier (BBB); Magnetic resonance imaging (MRI).